Faced with declining sales for its diabetes products, Sanofi SA shifted course in the first quarter to strengthen its specialty pharmaceutical business by acquiring the haemophilia product developer Bioverativ Inc and the antibody company Ablynx NV. ---Subscribe to MedNous to access this article--- Company News
